Company: TAK
Filing Date: 2025-06-27
Form Type: 424B2
Source: 0001628280-25-033198
Chunk: 16

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-27
Form: 424B2
Chunk 16
---
 |   ¥    849.7 |          |     |   ¥    533.5 |          |     |   ¥    457.8 |          |     | ¥385.1       |          |       |
| Total assets                                                                     |     |                                                             | 12,912.3 |     |              | 13,178.0 |     |              | 13,957.8 |     |              | 15,108.8 |     |              | 14,248.3 |       |
| Total bonds and loans                                                            |     |                                                     4,635.4 |          |     |      4,345.4 |          |     |      4,382.3 |          |     |      4,843.8 |          |     |              |  4,515.3 |       |
| Total liabilities                                                                |     |                                                     7,735.1 |          |     |      7,494.5 |          |     |      7,603.1 |          |     |      7,834.8 |          |     |              |  7,312.4 |       |
| Total equity                                                                     |     |                                                     5,177.2 |          |     |      5,683.5 |          |     |      6,354.7 |          |     |      7,274.0 |          |     |              |  6,936.0 |       |

<div align='center'>S-13</div>

### DESCRIPTION OF THE NOTES AND THE GUARANTEE
The following description supplements and, to the extent it is inconsistent, replaces the general description of the debt securities and the TUSFI Indenture contained in the accompanying prospectus under the caption “Description of Senior Debt Securities and Guarantee.” The following description of the Notes and the Guarantee is a summary of the detailed provisions of the Notes, the Guarantee and the TUSFI Indenture described herein. It does not purport to be complete. This summary is subject to and is qualified by reference to all the provisions of the Notes, the Guarantee and the TUSFI Indenture, including the definitions of certain terms used therein. You are urged to read those documents in their entirety because they, and not this description, define the rights of holders of the Notes. Capitalized terms used but not defined here or elsewhere in the prospectus supplement shall have the meaning prescribed to them in